Amylyx Pharmaceuticals (AMLX) Common Equity (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Common Equity of $273.2 million for Q1 2026, up 35.62% year-over-year from $201.4 million in Q1 2025, and down 10.52% quarter-over-quarter from $305.3 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Common Equity (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Common Equity history runs 6 years deep, the most recent figure standing at $273.2 million for Q1 2026.
- In Q1 2026, Common Equity rose 35.62% year-over-year to $273.2 million; the TTM figure through Mar 2026 stood at $273.2 million (up 35.62% YoY), while the FY2025 annual figure was $305.3 million, up 85.27% from the prior year.
- Common Equity for Q1 2026 stood at $273.2 million, down from $305.3 million in the prior quarter.
- The five-year high for Common Equity was $433.4 million in Q4 2023, with the low at $144.0 million in Q3 2022.
- The 5-year median for Common Equity is $273.2 million (2026), against an average of $278.6 million.
- The sharpest annual moves came in 2022 and 2024: Common Equity surged 398.83% in 2022, then plunged 61.99% in 2024.
- Amylyx Pharmaceuticals' Common Equity stood at $340.6 million in 2022, then climbed by 27.25% to $433.4 million in 2023, then slumped by 61.99% to $164.8 million in 2024, then soared by 85.27% to $305.3 million in 2025, then declined by 10.52% to $273.2 million in 2026.
- Business Quant data shows AMLX's Common Equity at $273.2 million in Q1 2026, $305.3 million in Q4 2025, and $332.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.71 Bn | 42.75 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.11 Bn | 39.45 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.62 Bn | 29.94 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.33 Bn | 19.67 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 12.10 Bn | 11.57 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 4.05 Bn |
| 10 | Amylyx Pharmaceuticals | 4.28 Bn | 4.28 Bn | - | 239.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 239.17 Mn |
| Mar 31, 2026 | 273.16 Mn |
| Dec 31, 2025 | 305.26 Mn |
| Sep 30, 2025 | 332.00 Mn |
| Jun 30, 2025 | 167.88 Mn |
| Mar 31, 2025 | 201.42 Mn |
| Dec 31, 2024 | 164.77 Mn |
| Sep 30, 2024 | 196.20 Mn |
| Jun 30, 2024 | 261.31 Mn |
| Mar 31, 2024 | 324.44 Mn |
| Dec 31, 2023 | 433.43 Mn |
| Sep 30, 2023 | 418.40 Mn |
| Jun 30, 2023 | 386.37 Mn |
| Mar 31, 2023 | 352.65 Mn |
| Dec 31, 2022 | 340.61 Mn |
| Sep 30, 2022 | 144.03 Mn |
| Jun 30, 2022 | 192.79 Mn |
| Mar 31, 2022 | 240.95 Mn |
| Dec 31, 2021 | -151.17 Mn |
| Sep 30, 2021 | -124.07 Mn |